Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY2027 Earnings Presentation
18 slides from Ngl Fine-chem's earnings presentation, Aug 17, 2026
Slide 1: Exchange covering letter for Investor Presentation Q1FY27
August 17, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Dalal Street, Fort, Bandra Kurla Complex, Bandra East, Mumbai 400 001. Mumbai 400051. Scrip Code: 524774 Symbol: NGLFINE Dear Sir/Madam, Sub: Investor Pres
Slide 2: NGL Fine-Chem Limited Investor Presentation Q1FY27
NGL Fine-Chem Limited INVESTOR PRESENTATION Q1FY27
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 10 Q1FY27 Over view, Highlights Key Strengths and Strategy Pg. No. 15 Historical Financial Performance
Slide 5: Q1FY27 Highlights
01 Q1FY27 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 08 SUMMARY OF BAL ANCE SHEET 09 S U M M A R Y O F C A S H F LO W S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, “Q1FY27 sustained the demand momentum we Against a loss of ₹4.5 crore in Q4FY26, we recorded witnessed in Q4FY26, with volumes remaining a forex gain of ₹2.5 crore in Q1FY27, providing a robust across our product segments and measurable uplift t o reported ea
Slide 7: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q1FY26 Q4FY26 Q1FY27 PARTICULARS Q1FY26 Q4FY26 Q1FY27 ANIMAL API 92% 95% 95% TOP 3 PRODUCTS 30% 29% 31% HUMAN API 4% 2% 3% TOP 5 PRODUCTS 42% 44% 48% INTERMEDIATES 3% 1% 1% TOP 10 PRODUCTS 63% 66% 68% FORMULATIONS
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q1FY26 Q4FY26 Q1FY27 Q-o-Q Y-o-Y REVENUE FROM OPERATIONS 104.19 149.23 139.16 -6.75% 33.57% OTHER INCOME 6.35 2.46 7.43 202.05% 16.91% TOTAL INCOME 110.54 151.69 146.59 -3.36% 32.61% TOTAL OPERATING EXPENSES 93.21 127.82 115.88 -9.35% 24.
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY25 FY26 SHAREHOLDERS FUND 282.43 329.23 NON CURRENT LIABILITIES 31.99 66.25 LONG TERM BORROWINGS 25.34 56.40 CURRENT LIABILITIES 118.97 150.01 SHORT TERM BORROWINGS 48.00 52.02 TOTAL EQUITY AND LIABILITIES 433.39 545.50 NON CURRENT ASSETS 198.01 26
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY25 FY26 CASH FLOW FROM OPERATING ACTIVITIES 32.36 43.32 CASH FLOW FROM INVESTING ACTIVITIES (69.68) (70.59) CASH FLOW FROM FINANCING ACTIVITIES 37.46 29.55 NET CASH FLOW 0.14 2.27 CASH AT THE BEGINNING OF YEAR 0.40 0.53 CASH AT THE END OF YEA
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 45 APIs (43 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~451 customers APIs, 2 Human
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 13% CAGR CONCENTRATION (OF SALES FY26) backward integrated facilities leading to cost competitiveness FY26 466 CUSTOMER PRODUCT F
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 5 manufacturing facilities located at Tarapur & Navi 20,000 m 2 168 kl 253 kl AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are ca
Slide 15: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • Capacity expansion with su
Slide 16: Historical Financial Performance
03 Historical Financial Performance 16 ROBUST FINANCIAL PERFORMANCE
Slide 17: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY26 501 FY26 73 FY26 48 FY25 368 FY25 34 FY25 21 FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 0 100 200 300 400 500 600 0 10 20 30 40 50 60 70 80 0 10 20 30 40 50 60 GROSS MARGIN
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Shivam Gharat Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, Maha